Friedman JM. Neurofibromatosis 1. GeneReviews®. Adam MP, Ardinger HH, Pagon RA, et al., Editors. Seattle, WA, USA: University of Washington, Seattle; 1993–2021. [Accessed July 2021] Available at: https://www.ncbi.nlm.nih.gov/books/NBK1109/.
Lammert M, Friedman JM, Kluwe L, Mautner VF. Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol. 2005; 141(1): 71–74.
Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010; 152A(2): 327–332.
Yang F, Xu S, Liu R, Shi T, Li X, Li X, et al. The investigation for potential modifier genes in patients with neurofibromatosis type 1 based on next-generation sequencing. Onco Targets Ther. 2018; 11: 919–932.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al.; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5): 405–424.
Anastasaki C, Le LQ, Kesterson RA, Gutmann DH. Updated nomenclature for human and mouse neurofibromatosis type 1 genes. Neurol Genet. 2017; 3(4): e169.
Cooper DN, Ball EV, Stenson PD, Phillips AD, Evans K, Heywood S, et al. The human gene mutation database at the Institute of Medical Genetics in Cardiff. [Accessed February 2021] Available at: http://www.hgmd.cf.ac.uk/ac/gene.php?gene=NF1).
Zhu G, Zheng Y, Liu Y, Yan A, Hu Z, Yang Y, et al. Identification and characterization of NF1 and no-NF1 congenital pseudoarthrosis of the tibia based on germline NF1 variants: Genetic and clinical analysis of 75 patients. Orphanet J Rare Dis. 2019; 14(1): 221.